Fosun Pharma's Amoxicillin Capsules Passes Consistency evalsuations for Generic Drugs
【4 Dec 2019, Hong Kong】 On 3 December 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) announced that its subsidiary Guilin Pharmaceutical (Shanghai) Co., Ltd. (“GPSC”) had received an Approval Document on the Drug Supplementary Application (batch no.: 2019B04284) from the National Medical Products Administration (“NMPA”), which indicated that the GPSC’s Amoxicillin Capsules (the “Drug”) had passed the consistency evalsuations for generic drugs.
Amoxicillin Capsules is mainly used for the treatment of adult and child infections caused by sensitive bacteria (no β-lactamase producing strains). The Drug is the first product of GPSC passing the consistency evalsuations and the first product in Guangxi passing the consistency evalsuations after the launch of the consistency evalsuation policy. Therefore, it has positive significance to the consistency evalsuations for generic drugs in Guangxi. Up until November 2019, GPSC’s cumulative R&D investment in the Drug’s consistency performance was some RMB6.55 million.
Fosun Pharma stated, that Amoxicillin Capsules has passed the consistency evalsuations for generic drugs can effectively increase its competitiveness in the market and be beneficial to market sales, while accumulating experience for the Company to conduct research on generic drug consistency evalsuation for other products in subsequent stage. In response to calls for centralized procurement of drugs covered by national health insurance, Fosun Pharma has focused on R&D innovation as its major development driving factor, so as to continuously bolster the pharmaceutical R&D system for generic-proprietary integration and actively promote the NMPA’s consistency evalsuations for generic drugs.
Amoxicillin Capsules is mainly used for the treatment of adult and child infections caused by sensitive bacteria (no β-lactamase producing strains). The Drug is the first product of GPSC passing the consistency evalsuations and the first product in Guangxi passing the consistency evalsuations after the launch of the consistency evalsuation policy. Therefore, it has positive significance to the consistency evalsuations for generic drugs in Guangxi. Up until November 2019, GPSC’s cumulative R&D investment in the Drug’s consistency performance was some RMB6.55 million.
Fosun Pharma stated, that Amoxicillin Capsules has passed the consistency evalsuations for generic drugs can effectively increase its competitiveness in the market and be beneficial to market sales, while accumulating experience for the Company to conduct research on generic drug consistency evalsuation for other products in subsequent stage. In response to calls for centralized procurement of drugs covered by national health insurance, Fosun Pharma has focused on R&D innovation as its major development driving factor, so as to continuously bolster the pharmaceutical R&D system for generic-proprietary integration and actively promote the NMPA’s consistency evalsuations for generic drugs.